文章核心观点 - 公司公布IMNN - 001的2期OVATION 2研究新阳性转化数据，其在治疗新诊断的晚期卵巢癌上有潜力，且与此前ASCO 2025上的总生存期结果互补，支持正在进行的3期试验 [1][3] 研究结果 - OVATION 2研究评估112名参与者，IMNN - 001治疗使IL - 12、IFN - γ和TNF - α分别增加约27、62和36倍，显示肿瘤局部效应且安全性良好 [2] - 2025年ASCO年会上和《妇科肿瘤学》文章中，IMNN - 001加标准治疗化疗在晚期卵巢癌患者的总生存期、无进展生存期等方面有改善，安全性良好 [3] 公司进展 - 公司正在推进IMNN - 001的关键3期OVATION 3研究，2025年5月已启动前两个试验点 [3] 关于2期OVATION 2研究 - 评估腹腔注射IMNN - 001联合新辅助和辅助化疗的剂量、安全性、疗效和生物活性，入组112名患者随机分组对比 [4] - 新辅助期治疗旨在缩小肿瘤以便手术切除，后续进行间隔减瘤手术和辅助化疗，研究未设统计学显著性检验，还有其他终点指标 [4] 关于IMNN - 001免疫疗法 - 基于公司专有TheraPlas平台技术设计，是包裹在纳米颗粒递送系统中的IL - 12 DNA质粒载体，能诱导抗癌免疫 [6] - 此前单药或联合治疗晚期卵巢癌有积极安全性和1期结果，完成1b期剂量递增试验和2期OVATION 2研究 [6] 关于上皮性卵巢癌 - 是美国女性第六大致命恶性肿瘤，每年约20000例新病例，约70%诊断为晚期，复发风险高，5年生存率低，需新疗法 [7] 关于公司 - 是临床阶段生物技术公司，开发非病毒DNA技术，有TheraPlas和PlaCCine两种模式 [8] - 主要临床项目IMNN - 001完成多项临床试验，还完成COVID - 19加强疫苗首次人体研究 [9]

Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilutive Capital LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptation of the platform’s potential as a next-generation vaccine, today ...

Imunon (IMNN) Conference June 12, 2025 11:30 AM ET Speaker0 Welcome to Virtual Investor Conferences. On behalf of the Life Science Investor Forum and our co host, Zach SmallCap Research, we're very pleased you our next presentation is from ImmuneOn. Please note you may submit questions for the presenter in the box to the left of the slides, and you can view a company's availability for one on one meetings by clicking Book Meeting in the top toolbar. This point, I'm very pleased to welcome Stacy Limborg. She ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of Imunon, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, June 12, 2025, at 11:30 a.m. ET. Pre-register for Imunon’s virtual presentation at the Virtual Investor Conferences site HERE. This will be a live, interactive online eve ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and BRCA2 mutations LAWRENCEVILLE, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 ...

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN) Dear Valued Shareholders, A Year of Breakthroughs: IMUNON Has Never Been Stronger As I mark my first year as President and CEO of IMUNON, I am thrilled to share the progress we have made in advancing our mission to transform cancer treat ...

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today closed on the previously announced sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an aggregate of ...

Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2 Study of IMNN-001 Simultaneously publication in leading peer-reviewed journal Gynecologic Oncology details IMNN-001’s outstanding safety and efficacy across multiple analyses and subgroups Treatment with IMNN-001 could represent new promise for estimated 40,000 women newly diagnosed with advanced ovarian cancer yearly in EU and 300,000 globally LAWRENCEVILLE, N.J., May ...

$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term ...

Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP inhibitors achieved nearly 12-month increase in PFS compared to standard of care; median OS in IMNN-001 treatment arm not yet reached after more than five years Phase 2 OVATION 2 Study results also published in peer-reviewed journal Gynecologic Oncology LAWRENCEVIL ...